Aura Biosciences (AURA) Cash from Investing Activities (2020 - 2026)

Aura Biosciences has reported Cash from Investing Activities for 7 years, with the latest figure at $54.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 84.14% year-over-year to $54.9 million; the trailing twelve-month figure through Mar 2026 stood at $60.7 million (down 32.0% YoY), and the FY2025 full-year result was $35.6 million, down 48.28% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $54.9 million, up from $29.8 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $54.9 million in Q1 2026, with the low at -$90.1 million in Q4 2023.
• Historically, Cash from Investing Activities has averaged -$1.3 million across 5 years, with a median of $17.9 million in 2022.
• The largest YoY upside for Cash from Investing Activities was 3231.94% in 2022 against a maximum downside of 35812.68% in 2022.
• Aura Biosciences' Cash from Investing Activities stood at -$16.9 million in 2022, then tumbled by 434.01% to -$90.1 million in 2023, then soared by 132.95% to $29.7 million in 2024, then climbed by 0.43% to $29.8 million in 2025, then soared by 84.07% to $54.9 million in 2026.
• The last three Cash from Investing Activities figures came in at $54.9 million (Q1 2026), $29.8 million (Q4 2025), and -$44.0 million (Q3 2025), per Business Quant data.